Mandate

Vinge advises FSN Capital in connection with acquisition of Saferoad

Vinge has, in its capacity as Swedish local counsel, advised FSN Capital V (“FSN Capital”) in connection with their buy-out of Saferoad Holding ASA (“Saferoad”), a company that is listed on the Oslo Stock Exchange.

Earlier in May, FSN Capital announced an agreement to launch a recommended voluntary cash offer to acquire the entire issued share capital of Saferoad, a Norwegian based market leading provider of road safety and road infrastructure products and solutions in Europe (#1 or #2 in its core niche markets). FSN Capital has received pre-acceptances from shareholders representing approximately 64% of Saferoad’s issued share capital. The transaction is subject to approval from the competition authorities, as well as other conditions including that more than 90% of the share capital accept the offer.
 
Vinge’s team consists of partner Christina Kokko together with, among others, associates Maria Dahlin, Hayaat Ibrahim, Oscar Wennerström, Karolina Cohrs, Elias Lundin, Sophia Holm and Jasmin Draszka-Ali.
 

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026